TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer

NCT06532812 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

85

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Breast Carcinoma
Breast Cancer Metastatic
Breast Cancer Triple Negative

Interventions

BIOLOGICAL: Tumor Infiltrating Lymphocytes (TIL)
DRUG: Cyclophosphamid
DRUG: Fludarabine
DRUG: Interleukin-2
DRUG: Pembrolizumab

Sponsor

Essen Biotech